1E is developing a new modality of RNA silencing (a well-established therapeutic class with over $5b in revenues in 2024 and 14 FDA approved drugs) that is independent of the cellular machinery, unlike current technology. This allows our technology to be highly specific—at the single letter level—allowing us to expand and disrupt the current market.